Oestrogen inhibits BMP4-induced BMP4 expression in cardiomyocytes: A potential mechanism of oestrogen-mediated protection against cardiac hypertrophy

British Journal of Pharmacology

Volumn 172, Issue 23, 2015, Pages 5586-5595

  Wang, Yu Chun ^a   Xiao, Xiao Lin ^a   Li, Na ^a   Yang, Di ^a   Xing, Yue ^a   Huo, Rong ^a   Liu, Ming Yu ^a   Zhang, Yan Qiu ^a   Dong, De Li ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 ( 2 PHENYL 5,7 BIS(TRIFLUOROMETHYL)PYRAZOL[1,5 A]PYRAMIDIN 3 YL)PHENOL; BONE MORPHOGENETIC PROTEIN 4; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHENOL; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; BMP4 PROTEIN, MOUSE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSVERSE AORTIC CONSTRICTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARDIAC MUSCLE CELL; CARDIOMEGALY; CELL CULTURE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; INBRED MOUSE STRAIN; METABOLISM; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BONE MORPHOGENETIC PROTEIN 4; CARDIOMEGALY; CELLS, CULTURED; ENZYME ACTIVATION; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; INJECTIONS, SUBCUTANEOUS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, INBRED STRAINS; MYOCYTES, CARDIAC; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84949534660     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12983     Document Type: Article

References (42)

1. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol, 170: 1797-1867.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
4. Babiker FA, De Windt LJ, van Eickels M, Thijssen V, Bronsaer RJ, Grohe C, et al. (2004). 17beta-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. Circulation 109: 269-276.
5. Babiker FA, Lips D, Meyer R, Delvaux E, Zandberg P, Janssen B, et al. (2006). Estrogen receptor beta protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol 26: 1524-1530.
6. Bell JR, Bernasochi GB, Varma U, Raaijmakers AJ, Delbridge LM, (2013). Sex and sex hormones in cardiac stress-mechanistic insights. J Steroid Biochem Mol Biol 137: 124-135.
7. Bendale DS, Karpe PA, Chhabra R, Shete SP, Shah H, Tikoo K, (2013). 17-β oestradiol prevents cardiovascular dysfunction in post-menopausal metabolic syndrome by affecting SIRT1/AMPK/H3 acetylation. Br J Pharmacol 170: 779-795.
8. Bhattacherjee A, Rumi MA, Staecker H, Smith PG, (2013). Bone morphogenetic protein 4 mediates estrogen-regulated sensory axon plasticity in the adult female reproductive tract. J Neurosci 33: 1050-1061a.
9. Cao J, Zhu T, Lu L, Geng L, Wang L, Zhang Q, et al. (2011). Estrogen induces cardioprotection in male C57BL/6J mice after acute myocardial infarction via decreased activity of matrix metalloproteinase-9 and increased Akt-Bcl-2 anti-apoptotic signaling. Int J Mol Med 28: 231-237.
10. Donaldson C, Eder S, Baker C, Aronovitz MJ, Weiss AD, Hall-Porter M, et al. (2009). Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation. Circ Res 104: 265-275, 211p following 275.
11. Dong DL, Chen C, Huo R, Wang N, Li Z, Tu YJ, et al. (2010). Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension 55: 946-952.
12. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA, (2001). 17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation 104: 1419-1423.
13. Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, Dworatzek E, et al. (2010). Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol 298: R1597-R1606.
14. Fujita T, Kawata T, Tokimasa C, Tanne K, (2001). Influence of oestrogen and androgen on modelling of the mandibular condylar bone in ovariectomized and orchiectomized growing mice. Arch Oral Biol 46: 57-65.
15. Grohe C, Kahlert S, Lobbert K, Vetter H, (1998). Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis. J Endocrinol 156: R1-R7.
16. Guo WT, Dong DL, (2014). Bone morphogenetic protein-4: a novel therapeutic target for pathological cardiac hypertrophy/heart failure. Heart Fail Rev 19: 781-788.
17. Gurgen D, Hegner B, Kusch A, Catar R, Chaykovska L, Hoff U, et al. (2011). Estrogen receptor-beta signals left ventricular hypertrophy sex differences in normotensive deoxycorticosterone acetate-salt mice. Hypertension 57: 648-654.
18. Hamilton KL, Gupta S, Knowlton AA, (2004). Estrogen and regulation of heat shock protein expression in female cardiomyocytes: cross-talk with NF kappa B signaling. J Mol Cell Cardiol 36: 577-584.
19. Hu CW, Li Q, Zhang Y, Li YH, Jiang HC, Liu MY, et al. (2014). Bone morphogenetic protein-4 induces upregulation of Cav3.1 Ca channels in HL-1 atrial myocytes. Pflugers Arch 466: 2049-2057.
20. Jankowski M, Rachelska G, Donghao W, McCann SM, Gutkowska J, (2001). Estrogen receptors activate atrial natriuretic peptide in the rat heart. Proc Natl Acad Sci U S A 98: 11765-11770.
21. Kararigas G, Fliegner D, Gustafsson JA, Regitz-Zagrosek V, (2011). Role of the estrogen/estrogen-receptor-beta axis in the genomic response to pressure overload-induced hypertrophy. Physiol Genomics 43: 438-446.
22. Khalil RA, (2013). Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol 86: 1627-1642.
23. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
24. Knowlton AA, Lee AR, (2012). Estrogen and the cardiovascular system. Pharmacol Ther 135: 54-70.
25. Liu H, Pedram A, Kim JK, (2011). Oestrogen prevents cardiomyocyte apoptosis by suppressing p38α-mediated activation of p53 and by down-regulating p53 inhibition on p38β. Cardiovasc Res 89: 119-128.
26. Lu J, Sun B, Huo R, Wang YC, Yang D, Xing Y, et al. (2014). Bone morphogenetic protein-2 antagonizes bone morphogenetic protein-4 induced cardiomyocyte hypertrophy and apoptosis. J Cell Physiol 229: 1503-1510.
27. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
28. Miyazono K, Maeda S, Imamura T, (2005). BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 16: 251-263.
29. Monsoro-Burq AH, Duprez D, Watanabe Y, Bontoux M, Vincent C, Brickell P, et al. (1996). The role of bone morphogenetic proteins in vertebral development. Development 122: 3607-3616.
30. Murphy E, (2011). Estrogen signaling and cardiovascular disease. Circ Res 109: 687-696.
31. Nuedling S, Kahlert S, Loebbert K, Doevendans PA, Meyer R, Vetter H, et al. (1999). 17 Beta-estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. Cardiovasc Res 43: 666-674.
32. Pachori AS, Custer L, Hansen D, Clapp S, Kemppa E, Klingensmith J, (2010). Bone morphogenetic protein 4 mediates myocardial ischemic injury through JNK-dependent signaling pathway. J Mol Cell Cardiol 48: 1255-1265.
33. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-D1106.
34. Pedram A, Razandi M, Lubahn D, Liu J, Vannan M, Levin ER, (2008). Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin. Endocrinology 149: 3361-3369.
35. Pedram A, Razandi M, Narayanan R, Dalton JT, McKinsey TA, Levin ER, (2013). Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell 24: 3805-3818.
36. Rockman CB, Maldonado TS, Jacobowitz GR, Adelman MA, Riles TS, (2012). Hormone replacement therapy is associated with a decreased prevalence of peripheral arterial disease in postmenopausal women. Ann Vasc Surg 26: 411-418.
37. Satoh M, Matter CM, Ogita H, Takeshita K, Wang CY, Dorn GW 2nd, et al. (2007). Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation 115: 3197-3204.
38. Skavdahl M, Steenbergen C, Clark J, Myers P, Demianenko T, Mao L, et al. (2005). Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol 288: H469-H476.
39. Sun B, Huo R, Sheng Y, Li Y, Xie X, Chen C, et al. (2013a). Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy. Hypertension 61: 352-360.
40. + channels in pathological cardiac hypertrophy. Biochem Biophys Res Commun 436: 591-594.
41. Urata Y, Ihara Y, Murata H, Goto S, Koji T, Yodoi J, et al. (2006). 17Beta-estradiol protects against oxidative stress-induced cell death through the glutathione/glutaredoxin-dependent redox regulation of Akt in myocardiac H9c2 cells. J Biol Chem 281: 13092-13102.
42. Zhou M, Wang Y, Qi S, Wang J, Zhang S, (2011). The expression of a mitochondria-localized glutamic acid-rich protein (MGARP/OSAP) is under the regulation of the HPG axis. Endocrinology 152: 2311-2320.